carbenoxolone sodium has been researched along with Metabolic Syndrome in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Hady, EA; Bahaa, I; Saleh, N; Seif, AA | 1 |
| Dhanesha, N; Dhote, V; Jain, M; Joharapurkar, A; Kshirsagar, S; Shah, G; Sharma, A | 1 |
| Acharya, V; Ayyalasomayajula, V; Koppala, SR; Nemani, H; Ponday, LR; Pothana, S; Prasad Sakamuri, SS; Prathipati, VK; Putcha, UK; Sukapaka, M; Veetill, GN | 1 |
| Chen, Y; Frevert, EU; Fung, S; Jacobson, P; Jae, HS; Link, JT; Monzon, K; Richards, S; Sham, H; Sorensen, B; Wang, J; Winn, M | 1 |
| Hachey, DL; Hasty, AH; Nuotio-Antar, AM | 1 |
| Stimson, RH; Walker, BR | 1 |
1 review(s) available for carbenoxolone sodium and Metabolic Syndrome
| Article | Year |
|---|---|
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Adult; Animals; Carbenoxolone; Cushing Syndrome; Diet; Glucocorticoids; Humans; Hyperandrogenism; Hypothalamo-Hypophyseal System; Liver; Male; Metabolic Syndrome; Mice; Mice, Knockout; Mice, Transgenic; Obesity; Organ Specificity; Pituitary-Adrenal System; Rats | 2007 |
5 other study(ies) available for carbenoxolone sodium and Metabolic Syndrome
| Article | Year |
|---|---|
Comparative effect of vitamin D3 and carbenoxolone treatments in metabolic syndrome rats.
Topics: Animals; Blood Glucose; Carbenoxolone; Cholecalciferol; Insulin Resistance; Metabolic Syndrome; Rats; Rats, Wistar | 2022 |
Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adiposity; Animals; Anti-Obesity Agents; Brain; Carbenoxolone; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Energy Metabolism; Enzyme Inhibitors; Female; Glucose-6-Phosphatase; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Mice; Mice, Mutant Strains; Obesity; Pancreas; Phosphoenolpyruvate Carboxykinase (ATP) | 2012 |
Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipocytes; Adipose Tissue; Adrenal Glands; Animals; Body Composition; Carbenoxolone; Cholesterol, HDL; Corticosterone; Eating; Enzyme Inhibitors; Fibrosis; Gene Expression Regulation; Glucose Intolerance; Glycogen; Hypertrophy; Liver; Male; Metabolic Syndrome; Obesity; Organ Size; Rats; Signal Transduction; Thinness; Triglycerides | 2012 |
Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Carbenoxolone; Enzyme Inhibitors; Humans; Metabolic Syndrome; Molecular Conformation; Piperazines; Sulfonamides; Thiazoles | 2006 |
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Agouti Signaling Protein; Animals; Atherosclerosis; Blood Pressure; Body Weight; Carbenoxolone; Corticosterone; Energy Metabolism; Fatty Liver; Female; Hyperinsulinism; Hyperlipidemias; Lipoproteins, VLDL; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; Receptors, LDL | 2007 |